Research identifies novel intracellular pathway important for collagen homeostasis

16 Sep 2016, 11 a.m.

A collaboration between researchers at UCL, led by BRC-funded Professor Paul Gissen, has identified a novel intracellular pathway important for generic collagen homeostasis. Furthermore, this pathway was found to be dependent on two proteins that are defective in Arthrogryposis Renal dysfunction and Cholestasis (ARC) syndrome.

Findings showed that regulation of post-Golgi LH3 trafficking is essential for collagen homeostasis and the development and function of multiple organs and tissues. This pathway was found to be dependent on the protein VIPAR and its partner proteins. These findings were confirmed in patients with ARC.

ARC syndrome is a multisystem disorder, characterised by defects of the musculoskeletal system and LH3-specific collagen modification levels are reduced in these patients. Findings showed functional collagen abnormalities in cells and tissues of these patients, which are caused by VIPAR and VPS33B deficiencies, suggesting that these deficiencies result in abnormal LH3-dependent post-translational modification of collagen in these patients. Furthermore, Kevin Mills’ laboratory, funded by the BRC discovered urine biomarkers that will allow easy and early diagnosis in these patients which could help avoid unnecessary investigations.

Findings have been published in Nature Communications.

Genomics will revolutionise treatment for childhood rare diseases

A global study has proven the power of a simple genomics blood test to improve treatment and care for childhood epilepsy.

Join us in the countdown to Rare Disease Day 2025

Rare Disease Day takes place annually on the last day of February and is a global opportunity to increase awareness and advocate for those living with rare conditions.

Twelve days of Research and Innovation at GOSH

It’s been a busy year for Research and Innovation at GOSH, with a number of ground breaking research trials, advanced data projects and technology pilots. To round off the year, here are just twelve of the stories (and amazing staff and researchers) that

World-first genomic testing scheme ensures every child gets the best cancer treatment for them

Children with cancer are being offered treatment plans tailored to their specific cancer thanks to a single genomic test that reads more than three billion letters of DNA to identify cancer-causing mutations.